EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies

Rohit Singh iD, Pankaj Chandley iD, Soma Rohatgi iD

ImmunoHorizons · 01.12.2023 · 7 (12) · 886-897

DOI: 10.4049/immunohorizons.2300102 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ImmunoHorizons, online erschienen am 27.12.2023. Verfasst von Rohit Singh und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Uttarakhand, India. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

mAbs are highly indispensable tools for diagnostic, prophylactic, and therapeutic applications. The first technique, hybridoma technology, was based on fusion of B lymphocytes with myeloma cells, which resulted in generation of single mAbs against a specific Ag. Along with hybridoma technology, several novel and alternative methods have been developed to improve mAb generation, ranging from electrofusion to the discovery of completely novel technologies such as B cell immortalization; phage, yeast, bacterial, ribosome, and mammalian display systems; DNA/RNA encoded Abs; single B cell technology; transgenic animals; and artificial intelligence/machine learning. This commentary outlines the evolution, methodology, advantages, and limitations of various mAb production techniques. Furthermore, with the advent of next-generation Ab technologies such as single-chain variable fragments, nanobodies, bispecific Abs, Fc-engineered Abs, Ab biosimilars, Ab mimetics, and Ab-drug conjugates, the healthcare and pharmaceutical sectors have become resourceful to develop highly specific mAb treatments against various diseases such as cancer and autoimmune and infectious diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalBiosimilar PharmaceuticalsAnimalsArtificial IntelligenceHybridomasAnimals, Genetically ModifiedMammals

Substanzen

Antibodies, MonoclonalBiosimilar Pharmaceuticals

Autor:innen und Institutionen

  • Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee, Uttarakhand, India.

ORCID-Profile: Rohit Singh, Pankaj Chandley, Soma Rohatgi

Zitieren

APA

Singh, R., Chandley, P., & Rohatgi, S. (2023). Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies. ImmunoHorizons, 7(12), 886-897. https://doi.org/10.4049/immunohorizons.2300102

Vancouver

Singh R, Chandley P, Rohatgi S. Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies. ImmunoHorizons. 2023;7(12):886-897. doi:10.4049/immunohorizons.2300102

BibTeX
@article{Singh2023,
  author = {Singh, Rohit and Chandley, Pankaj and Rohatgi, Soma},
  title = {Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies},
  journal = {ImmunoHorizons},
  year = {2023},
  volume = {7},
  number = {12},
  pages = {886--897},
  doi = {10.4049/immunohorizons.2300102}
}
Kostenlos starten →